ALRN Stock - Aileron Therapeutics, Inc.
Unlock GoAI Insights for ALRN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-119,000 | $-169,000 | $-121,000 | $-163,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-65,112,000 | $-16,276,000 | $-27,647,000 | $-26,605,000 | $-20,496,000 |
| Net Income | $-62,883,000 | $-15,732,000 | $-27,011,000 | $-25,764,000 | $-21,818,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.51 | $-3.42 | $-5.95 | $-5.80 | $-12.52 |
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Visit WebsiteEarnings History & Surprises
ALRNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-0.21 | — | — |
Q3 2025 | Aug 12, 2025 | — | $-282.05 | — | — |
Q4 2024 | Nov 14, 2024 | $-0.25 | $-0.27 | -8.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.25 | $-0.45 | -80.0% | ✗ MISS |
Q2 2024 | Apr 15, 2024 | $-0.14 | $-1.54 | -1000.0% | ✗ MISS |
Q1 2024 | Mar 25, 2024 | $-0.16 | $-1.54 | -862.5% | ✗ MISS |
Q4 2023 | Oct 13, 2023 | $-0.20 | $-0.40 | -100.0% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.86 | $-0.82 | +4.7% | ✓ BEAT |
Q1 2023 | Mar 20, 2023 | $-1.34 | $-1.02 | +23.9% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $-1.60 | $-1.40 | +12.5% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-1.80 | $-1.80 | 0.0% | = MET |
Q2 2022 | May 5, 2022 | $-1.60 | $-1.80 | -12.5% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-1.60 | $-1.60 | 0.0% | = MET |
Q4 2021 | Nov 12, 2021 | $-1.40 | $-1.40 | 0.0% | = MET |
Q3 2021 | Aug 11, 2021 | $-1.40 | $-1.20 | +14.3% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-1.20 | $-1.60 | -33.3% | ✗ MISS |
Q1 2021 | Mar 24, 2021 | $-2.20 | $-2.40 | -9.1% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-2.00 | $-2.60 | -30.0% | ✗ MISS |
Q3 2020 | Aug 5, 2020 | $-3.20 | $-2.80 | +12.5% | ✓ BEAT |
Latest News
Frequently Asked Questions about ALRN
What is ALRN's current stock price?
What is the analyst price target for ALRN?
What sector is Aileron Therapeutics, Inc. in?
What is ALRN's market cap?
Does ALRN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALRN for comparison